GlassScriptPhysician profile
Clarence Hall
NPI 1487730362
$1,733.63
in general payments reported to CMS, 2019-2025
23 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $147 · 2022: $59.94 · 2023: $325 · 2024: $479 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $223.90 | 2019-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.53 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $135.82 | 2019 | |
| Abbott Laboratories | $132.23 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $122.03 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $120.43 | 2019-2024 | Jardiance, Trulicity, Mounjaro |
| Pfizer INC. | $99.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $87.17 | 2020-2024 | Shingrix, Trelegy Ellipta |
| Medtronic, INC. | $85.92 | 2023-2024 | Closurefast, Venaseal |
| Merck Sharp & Dohme LLC | $81.84 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $78.85 | 2019-2024 | Eliquis |
| Lundbeck LLC | $78.01 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $66.14 | 2019-2025 | Breztri |
| Phathom Pharmaceuticals, INC. | $58.06 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $39.66 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.58 | 2019 | |
| Dexcom, INC. | $17.26 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.56 | 2024 | Caplyta |
| Abbvie INC. | $15.36 | 2023 | |
| Alkermes, INC. | $15.23 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.79 | 2024 | Fanapt |
| Grifols USA, LLC | $11.68 | 2019 | |
| Allergan, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.